Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186680
Status:
COMPLETED
Last Update Posted:
2010-03-02
First Post:
2005-09-14
Brief Title:
CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Selection of CD34THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU Cyclophosphamide Cisplatin for Stage IV Breast Cancer Limited Prior Treatment
Status:
COMPLETED
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the feasibility and safety of autologous transplantation of CD34Thy-1 hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer
Detailed Description:
Selection of CD34THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment with BCNU Cyclophosphamide Cisplatin for Stage IV Breast Cancer Limited Prior Treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCT00186680 | None | None | None |
| BMT86 | None | None | None |